跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
Health Canada
/
KANJINTI
Authorized
STANDARD
KANJINTI
Amgen Canada Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
4f9614785296a7a6
Company
Amgen Canada Inc
Type
Standard
Approval Details
Approval Id
4f9614785296a7a6
Drug Approval Canada Name
KANJINTI
Product Name
KANJINTI
Status
Marketed
Status Date
2021-10-07
Original Market Date
2021-10-07
Din
02518244
Drug Class
Human
Dosage Form
Powder For Solution
Route Of Administration
Intravenous
Schedule
Prescription , Schedule D
Ahfs
10:00.00
Atc Original
L01FD01 TRASTUZUMAB
Atc Name
l 01 fd 01
Aig Number
0154252002
Company Name
Amgen Canada Inc
Company Address
300, 6775 Financial Drive, Mississauga, Ontario, Canada, L5N 0A4
Active Ingredients
TRASTUZUMAB
150 MG / VIAL
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
4f9614785296a7a6
Type
Standard
Back to Health Canada Approvals